Renal Function Dips in First Year After Bladder Cancer Trimodal Therapy
Trimodal therapy for bladder cancer results in a slight decline in eGFR in the first year but stabilizes thereafter for up to 10 years, a study found.
Chemotherapy
Post-Cystectomy Long-Term Follow-Up Needed Even If No Sign of Bladder Cancer
A retrospective study showed that recurrence of bladder cancer after radical cystectomy can occur up to 4 years after surgery.
Neoadjuvant Mitomycin C Appears Effective in NMIBC
A 2-dose regimen effectively delivers mitomycin C to the bladder tissue before TURBT, investigators reported.
Exercise Intervention During Chemotherapy Beneficial
Intervention during chemo linked to lower decreases in VO2peak, health-related QoL, muscle strength immediately postchemotherapy
CKD, Albuminuria Risk Factors Identified in Childhood Cancer Survivors
Achieving normal blood pressure in childhood cancer survivors is “extremely important” for preventing CKD, according to investigators.
Enfortumab Vedotin Plus Pembrolizumab ‘Promising’ for Untreated Advanced Urothelial Carcinoma
Patients with advanced urothelial carcinoma treated with first-line enfortumab vedotin plus pembrolizumab had a 93.3% disease control rate.
Metastatic Prostate Cancer: Investigators Ponder New Path to Improve Survival
Greater effort should be directed at detecting and aggressively treating prostate cancer metastasis earlier, an approach made possible with the advent of highly sensitive and specific molecular imaging techniques and potent anticancer agents.
Local Docetaxel Therapy May Benefit Patients With High-Risk NMIBC
Of 19 patients with high-risk NMIBC treated with local docetaxel, 14 had prior BCG exposure.
Survival Improving in Metastatic Castration-Sensitive Prostate Cancer Population
Increase in survival of men with mCSPC during 2015-2019 coincides with the use of docetaxel and novel hormonal therapies for this disease state.
Tislelizumab Shows Promising Antitumor Benefits in Advanced Bladder Cancer
In a small retrospective pilot study, the checkpoint inhibitor tislelizumab added to gemcitabine/cisplatin improved progression-free survival compared with gemcitabine/cisplatin alone among patients with locally advanced or metastatic bladder cancer.
- Loading...
Loading...
Next post in Bladder Cancer
Loading... 
Loading...